NEW YORK (GenomeWeb News) – WaferGen Biosystems saw its second-quarter revenues fall 55 percent year over year, while its net loss narrowed sharply, it disclosed after the close of the market on Friday.

In its Form 10-Q filed with the US Securities and Exchange Commission, the Fremont, Calif.-based firm said that revenues for the quarter totaled $20,158, down from $44,905 a year ago, primarily due to lower sales of the Real-Time PCR Chip panels and of the SmartSlide consumables.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.